Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global E Online Ltd (GLBE) vs Viatris Inc (VTRS) Price & Performance

Global E Online LtdTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Global E Online Ltd vs Viatris Inc — how do they compare? Global E Online Ltd trades at $40.26 (market cap $6.75B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3× Global E Online Ltd's market cap, and Viatris Inc pays a 2.75% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Viatris Inc for 57 Days on average.

GLBEVTRS
Market Cap
$6.75B$20.03B
Volume
1,468,70814,109,977
Sector
Consumer CyclicalHealth
52-Week High
$42.36$18.27
52-Week Low
$27.54$9.74
Typical Hold Time
21 Days57 Days
Enterprise Value
$6.24B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global E Online Ltd

GLBE trades at $38.96, up 0.67% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year 2026 outlook. Revenue grew 39% year-over-year in Q2, with an adjusted EBITDA margin expansion to 20.9%. Analyst consensus is strongly bullish with a $48.86 price target, though recent insider selling and a high P/E ratio of 45.65 warrant attention.

The outlook for GLBE is positive based on robust revenue growth and raised guidance, but risks include high valuation multiples and insider selling activity. The stock presents a growth opportunity if execution continues, yet investors should weigh the premium valuation against future earnings potential amid competitive e-commerce markets.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →